Pharmacology in Pregnancy and Breast Feeding Flashcards

1
Q

What are the four basic pharmacokinetic processes?

A
  • absorption
  • distribution
  • metabolism and elimination
  • excretion
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Absorption changes during pregnancy

A
  • Oral route
    • May be more difficult “morning sickness” nausea/vomiting
    • Decrease in gastric emptying and gut motility
    • This is unlikely to be a problem with regular dosing, but may affect single doses
  • Intramuscular route
    • Blood flow may be increased, so absorption may also increase using this route
  • Inhalation
    • Increased cardiac output and increased tidal volume may cause increased absorption of inhaled drugs
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Distribution changes during pregnancy

A
  • Increase in plasma volume and fat will change distribution of drugs
  • Greater dilution of plasma will decrease relative amount of plasma proteins
  • Increased Fraction of Free Drug
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Metabolism changes during pregnancy

A

Oestrogen and progestogens can induce or inhibit liver P450 enzymes, increasing or reducing metabolism.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Excretion changes during pregnancy

A
  • GFR is increased in pregnancy by 50% leading to increased excretion of many drugs.
  • This can reduce the plasma concentration, and can necessitate an increase in dose of renally cleared drugs.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Pharmacodynamic changes during pregnancy

A
  • Pregnancy may affect site of action & receptor response to drugs
  • Concentration of drug and metabolites at sites of biological action (changes in blood flow)
  • Mechanism of action (changes in receptors)
  • Efficacy may be different
  • Adverse effects may be different
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What does placental transfer of drugs depend on?

A
  • Molecular weight (smaller sizes will cross more easily)
  • Polarity (non-polar cross more readily)
  • Lipid solubility (lipid soluble drugs will cross)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Foetal pharmacokinetics distribution

A
  • Circulation different (e.g. Umbilical vein to liver)
  • Less protein binding than adults therefore more “free” drug available
  • Little fat, so distribution different
  • Relatively more blood flow to brain
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Foetal pharmacokinetics metabolism

A
  • Less enzyme activity, though increases with gestation
  • Different isoenzymes to adults
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Foetal pharmacokinetics excretion

A
  • NB excretion is into amniotic fluid - this is swallowed and can allow recirculation
  • Drugs and metabolites can accumulate in amniotic fluid
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What causes drugs to be unsafe during pregnancy?

A
  • Teratogenicity (first trimester)
  • Fetotoxicity (second and third trimester)
  • NB Under treatment of chronic illnesses due to fear of using drugs during pregnancy may cause greater fetal risk!
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

When is the biggest risk of teratogenicity?

A

During organogenesis - weeks 3-8

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What are some mechanisms of teratogenicity?

A
  • Folate Antagonism
  • Neural Crest Cell Disruption
  • Specific Receptor or Enzyme-mediated Teratogenesis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Folate antagonism result

A
  • Key process in DNA formation and new cell production
  • Tend to result in neural tube, oro-facial or limb defects
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Which groups of drugs cause folate antagonism?

A

Two groups of drugs

  • Block the conversion of folate to THF by binding irreversibly to the enzyme (eg methotrexate, trimethoprim)
  • Block other enzymes in the pathway (eg phenytoin, carbamazepine, valproate)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Neural crest cell disruption - problems

A
  • aortic arch anomalies
  • ventricular septal defects
  • craniofacial malformations
  • oesophageal atresia
  • pharyngeal gland abnormalities
17
Q

Neural crest cell disruption - causes

A

Retinoid drugs (eg isotretinoin)

18
Q

Enzyme-mediated teratogenesis

A

Drugs which cause inhibition or stimulation of enzymes to produce therapeutic effects may also interact with specific receptors and enzymes damaging foetal development.

19
Q

Fetotoxicity

A
  • Toxic effect on the fetus later in pregnancy
  • Possible issues
    • Growth retardation
    • Structural malformations
    • Foetal death
    • Functional impairment
    • Carcinogenesis
  • Example ACE inhibitors/ARBs – renal dysfunction and growth retardation
20
Q

Drugs to avoid in breast feeding

A
  • Cytotoxics
  • Immunosuppressants
  • Anti-convulsants (not all)
  • Drugs of abuse
  • Amiodarone
  • Lithium
  • Radio-iodine
21
Q

Principles of prescribing for women of child-bearing age

A
  • Always consider possibility of pregnancy
  • Warn women of possible risks
  • When treating medical conditions, advise women to attend before getting pregnant if planning to (optimise treatment)
  • Discuss contraception
  • If necessary, do not prescribe without contraception
22
Q

Principles of prescribing in pregnancy

A
  • If possible, try non-pharmacological treatment first
  • Use the drug with the best safety record (avoid new drugs unless proven safe
  • Use the lowest effective dose
  • Use the drug for the shortest possible time, intermittently if possible
  • Avoid the first 10 weeks of pregnancy if possible
  • Consider stopping or reducing dose before delivery
  • Don’t under treat disease which may be harmful to the foetus
23
Q

Principles of prescribing in breast feeding

A
  • Avoid unnecessary drug use
  • Check on up to date drug information
  • If licensed and safe in paediatric use (esp under 2 years), a drug is likely to be safe in breast feeding
  • Choose drugs with pharmacokinetic properties that reduce infant exposure (eg highly protein bound)